{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:39:25Z","timestamp":1779248365139,"version":"3.51.4"},"reference-count":23,"publisher":"Medical Association of Nippon Medical School","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2022,12,25]]},"DOI":"10.1272\/jnms.jnms.2022_89-613","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T22:11:16Z","timestamp":1675203076000},"page":"587-593","source":"Crossref","is-referenced-by-count":8,"title":["Association of Transition of Laboratory Markers with Transition of Disease Activity in Psoriasis Patients Treated with Biologics"],"prefix":"10.1272","volume":"89","author":[{"given":"Setsuaki","family":"Annen","sequence":"first","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Horiguchi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Teramukai","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Ichiyama","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Hoashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kanda N, Hoashi T, Saeki H. Nutrition and psoriasis. Int J Mol Sci. 2020 Jul;21 (5):5405.","DOI":"10.3390\/ijms21155405"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kanda N, Hoashi T, Saeki H. The defect in regulatory T cells in psoriasis and therapeutic approaches. J Clin Med. 2021 Aug;10 (17):3880.","DOI":"10.3390\/jcm10173880"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis arthritis. Br J Dermatol. 2008 Aug;159 (2):322-30.","DOI":"10.1111\/j.1365-2133.2008.08628.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G, Girolomoni G. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol. 2013 Apr;168 (4):749-55.","DOI":"10.1111\/bjd.12118"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Strober BE, Poulin Y, Teller C, Wang Y, Williams DA, Goldblum OM. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. J Eur Acad Dermatol Venereol. 2014 Dec;28 (12):1701-6.","DOI":"10.1111\/jdv.12372"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol. 2014 Jun;28 (6):700-11.","DOI":"10.1111\/jdv.12257"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Pina T, Genre F, Lopez-Mejias R, et al. Anti-TNF-\u03b1 therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month retrospective study. J Eur Acad Dermatol Venereol. 2016 Jan;30 (1):92-5.","DOI":"10.1111\/jdv.13005"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Asahina A, Umezawa Y, Yanaba K, Nakagawa H. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: long-term differential effects of biologics. J Dermatol. 2016 Jul;43 (7):779-84.","DOI":"10.1111\/1346-8138.13213"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sen BB, Rifaioglu EN, Ekiz O, Inan MU, Sen N. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in psoriasis. Cutan Ocul Toxicol. 2014 Sep;33 (3):223-7.","DOI":"10.3109\/15569527.2013.834498"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yurtda\u015f M, Yaylali YT, Kaya Y, Ozdemir M, Ozkan I, Alada\u011f N. Neutrophil-to-lymphocyte ratio may predict subclinical atherosclerosis in patients with psoriasis. Echocardiography. 2014 Oct;31 (9):1095-104.","DOI":"10.1111\/echo.12511"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ataseven A, Bilgin AU, Kurtipek GS. The importance of neutrophil lymphocyte ratio in patients with psoriasis. Mater Sociomed. 2014 Aug;26 (4):231-3.","DOI":"10.5455\/msm.2014.231-233"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kim DS, Shin D, Lee MS, et al. Assessment of neutrophil to lymphocyte ratio and platelet to lymphocyte ration in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol. 2016 Mar;43 (3):305-10.","DOI":"10.1111\/1346-8138.13061"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Asahina A, Kubo N, Umezawa Y, Honda H, Yanaba K, Nakagawa H. Neutrophil-lymphocyte ration, platelet-lymphocyte ratio and mean platelet volume in Japanese patients with psoriasis and psoriatic arthritis: Response to therapy with biologics. J Dermatol. 2017 Oct;44 (10):1112-21.","DOI":"10.1111\/1346-8138.13875"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Akta\u015f Karabay E, Demir D, Aksu \u00c7erman A. Evaluation of monocyte to high-density lipoprotein ratio, lymphocytes, monocytes, and platelets in psoriasis. An Bras Dermatol. 2020 Jun-Feb;95 (1):40-5.","DOI":"10.1016\/j.abd.2019.05.002"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020 Mar;47 (3):201-22.","DOI":"10.1111\/1346-8138.15196"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54 (8):2665-73.","DOI":"10.1002\/art.21972"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica. 1978;157 (4):238-44.","DOI":"10.1159\/000250839"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Mizuno M, Horiguchi G, Teramukai S, et al. Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab. Australas J Dermatol. 2021 Nov;62 (4):e504-9.","DOI":"10.1111\/ajd.13719"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001 Mar;107 (3):535-41.","DOI":"10.1067\/mai.2001.113237"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil to lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012 Jan;5 (1):2.","DOI":"10.1186\/1755-7682-5-2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Feng F, Tian Y, Liu S, et al. Combination of PLR, MLR MWR, and tumor size could significantly increase the prognostic value for gastrointestinal stromal tumors. Medicine (Baltimore). 2016 Apr;95 (14):e3248.","DOI":"10.1097\/MD.0000000000003248"},{"key":"22","unstructured":"22. Tamaki K, Saeki H, Kadono T, et al. Atopisei hifuen no byosei shihyo toshiteno kessei TARC\/CCL17 chi nitsuiteno rinshoteki kento [Serum TARC\/CCL17 levels as a disease marker of atopic dermatitis]. Jpn J Dermatol. 2006 Jan;116 (1):27-39. Japanese."},{"key":"23","unstructured":"23. van Riel PL. The development of the disease score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol. 2014 Sep-Oct;32 (5 Suppl 85):S65-74."}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/6\/89_JNMS.2022_89-613\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T04:59:27Z","timestamp":1675486767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/89\/6\/89_JNMS.2022_89-613\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,25]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2022_89-613","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,25]]},"article-number":"JNMS.2022_89-613"}}